FierceBiotech Radio on biotech's Wall Street malaise, Valeant's Washington woes, and immuno-oncology's primetime slot

FiercePharma's Carly Helfand and FierceBiotech's Damian Garde discuss another rough week for biotech stocks, Valeant Pharmaceuticals' doggedness in the face of congressional inquiry, and a curious new trend in pharma advertising.

Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected]

Suggested Articles

The action will see Kiadis switch its attention to earlier-stage natural killer cell therapies against solid tumors and hematological cancers.

The Weill Family Foundation is stumping up $106 million to create a so-called “Neurohub.”

The takeover centers on TRPML1 agonists designed to treat neurodegenerative disorders by clearing toxic proteins from the brain.